Trials / Completed
CompletedNCT00902369
A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- Sponsor
- Asahi Kasei Therapeutics Corporation · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This will be a Phase II, multi-centre study consisting of 2 parts. Part 1: Clinical Pharmacology Study (drug-drug interaction between AK106-001616 and methotrexate) Part 2: Proof of Concept Study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK106-001616 | Part1: Dose escalation Part2: Dose expansion |
| DRUG | Placebo | |
| DRUG | Active comparator |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2009-10-01
- Completion
- 2010-07-01
- First posted
- 2009-05-15
- Last updated
- 2016-07-25
Locations
12 sites across 6 countries: Czechia, Germany, Hungary, Lithuania, Romania, United Kingdom
Source: ClinicalTrials.gov record NCT00902369. Inclusion in this directory is not an endorsement.